Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EPRX is a good fit for your portfolio.
News
-
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
-
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
-
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
-
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
-
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
-
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
-
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
Trading Information
- Previous Close Price
- CAD 3.94
- Day Range
- CAD 3.98–4.10
- 52-Week Range
- CAD 3.44–9.10
- Bid/Ask
- CAD 3.91 / CAD 4.07
- Market Cap
- CAD 144.98 Mil
- Volume/Avg
- 77,941 / 63,761
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.eupraxiapharma.com
Comparables
Valuation
Metric
|
EPRX
|
ICVX
|
PNT
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 5.49 | 3.30 | 3.12 |
Price/Sales | — | — | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
EPRX
ICVX
PNT
Financial Strength
Metric
|
EPRX
|
ICVX
|
PNT
|
---|---|---|---|
Quick Ratio | 1.95 | 17.59 | 9.01 |
Current Ratio | 1.95 | 18.06 | 9.14 |
Interest Coverage | −20.81 | — | — |
Quick Ratio
EPRX
ICVX
PNT
Profitability
Metric
|
EPRX
|
ICVX
|
PNT
|
---|---|---|---|
Return on Assets (Normalized) | −110.02% | −29.30% | 20.67% |
Return on Equity (Normalized) | −1,057.66% | −31.87% | 23.56% |
Return on Invested Capital (Normalized) | −143.54% | −34.69% | 23.38% |
Return on Assets
EPRX
ICVX
PNT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zmqyktjrn | Ylgfv | $598.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dhsknxzz | Lbvmrf | $115.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lcyhdzh | Hppbj | $109.5 Bil | |
MRNA
| Moderna Inc | Gpyfhdrf | Gmfwm | $54.0 Bil | |
BNTX
| BioNTech SE ADR | Rdjqmtqn | Yqxz | $24.7 Bil | |
ARGX
| argenx SE ADR | Dflbrfd | Jfyz | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bqjrygbl | Gvsynr | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gxnzctz | Dyrqkz | $14.5 Bil | |
INCY
| Incyte Corp | Jbnlkhdw | Gvmcf | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dcffnhpy | Pbcdkq | $12.3 Bil |